The core technology that supports the company's sustainable development is our independently constructed integrated drug innovation and early evaluation technology system based on chemical genomics. This platform system effectively integrates a number of modern technologies including computer-aided drug design, drug and combinatorial chemistry, high-throughput and high-content drug screening, chemical genomics gene expression profile research, bioinformatics and chemoinformatics data mining, and can Effectively accelerating the research and development process of innovative small molecule drugs and reducing the risks of new drug development are important technologies for developing new drugs with clinical differentiation, and are also an important guarantee for supporting the sustainable development of Microchip Biotech in the future.
Based on the rules of international new drug research and development and combined with the current situation of the Chinese pharmaceutical market, Microchip Biotech has explored a way to authorize patents to international pharmaceutical companies and establish international clinical joint development while retaining the business rights and interests of Chinese products. The road to corporate development to realize profits; at the same time, establish a business model for high-level cooperative research with multinational pharmaceutical companies. Through this development strategy, ChipBio's innovative drugs under development can not only be marketed in China as soon as possible, but also achieve the goal of entering the global market for Chinese original drugs in the future through the international clinical joint development model. This innovative development model - achieving profitability and development through patent authorization, cooperative research and final product sales - has changed the substantial shortcoming of China's local pharmaceutical companies lacking original drugs, and pioneered the transition from "Chinese generics" to "Chinese creations". "The first of its kind.
Since its establishment, Microchip Biotech has focused on establishing a corporate development strategy with patents and innovative drugs as its core competitiveness, and has made breakthrough progress in new drug research and development, intellectual property rights, business development, etc., and has achieved Ranked first in many industries and made positive contributions to China's innovative drug industry. As a Chinese innovative pharmaceutical company integrating independent innovation and cutting-edge platform technology, it has attracted the attention of the industry and media since its establishment. It has been included in the US "Business Week", "Times", "Nature Biotechnology", etc. Reported by magazines and media. He has been invited to give keynote speeches on new drug research and development at major international biomedical industry conferences many times, laying the foundation for the company's influence in the domestic and international pharmaceutical fields.